PHC-HOLDINGS
3.9.2021 12:41:06 CEST | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global life science, diagnostics and medical device company, has today announced the appointment of William (Bill) Donnelly and Ivan Tornos as independent external directors, effective September 3, 2021. Both bring significant expertise and executive-level experience at global medical device and life sciences companies.
Mr. Donnelly joins the board with almost 25 years’ experience in the laboratory equipment industry. Mr. Donnelly was most recently the Executive Vice President responsible for Finance, Supply Chain, Manufacturing and IT for Mettler-Toledo. Prior to becoming Executive Vice President, he held various senior executive positions, including Group CFO and as a Global Business Leader for one of Mettler-Toledo’s Divisions. Prior to this he was Chief Financial Officer at Elsag Bailey Process Automation, a market leader in industrial instrumentation and systems for the process control industry. He started his career working as an auditor for Price Waterhouse for 10 years. He is currently an Independent Director of Ingersoll Rand and PST, as well as the Board Chair for John Carroll University.
Mr. Tornos joins the board with almost 25 years’ experience in the medical device industry. Mr. Tornos is currently the Chief Operating Officer at Zimmer Biomet, responsible for overseeing all global businesses and leading the global operations, clinical and medical education, and global R&D functions. Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics and was later Group President, Global Businesses and the Americas, before becoming COO earlier this year. Prior to joining Zimmer Biomet, Mr. Tornos was Worldwide President of the Global Urology Group, Medical, and Critical Care Divisions at Becton Dickinson Interventional. He has also held global senior leadership positions in commercial, business development and operations for Covidien International, Baxter International, Johnson & Johnson and Bausch & Lomb.
John Marotta, President, CEO and Chairman of the Board of Directors for PHCHD said, "I am thrilled to have Bill and Ivan join the PHC Holdings Board of Directors. These are two exceptional industry leaders who will add vast experience and capabilities to our board. We are a global company and have set out to add individuals to our board who have deep expertise and diverse perspectives that can help with all aspects of our business. Bill and Ivan’s industry knowledge and strategic guidance will be immensely valuable to the future success of the PHC Group."
Hiro Hirano, Co-Head of Private Equity for KKR Asia and CEO of KKR Japan Limited, and member of the Board of Directors for PHCHD, added, “We are excited about the addition of Bill and Ivan to the PHC Holdings Board of Directors. We have worked to assemble a board with a range of experiences in operational and financial disciplines, and these additions take the board a key step forward in expanding our capabilities. We believe we have the right mix of global leaders who can support the next chapter in the evolution of our business.”
The addition of these new independent external directors follows the recent appointment of Mr. Alan Malus and Ms. Kyoko (Kay) Deguchi in July 2021.
John Marotta added, "Diversity is a high priority for PHC Holdings and all of our operating companies. As we continue to evolve in our journey of diversity and inclusion, we will further evolve our Board of Directors as a part of this initiative.”
About PHC Holdings Corporation
PHC Holdings Corporation is a global healthcare company with subsidiaries including PHC Corporation, Ascensia Diabetes Care, Epredia, and LSI Medience Corporation. Committed to its corporate mission that states, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company develops, manufactures, sells and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The PHC Group’s consolidated net sales in FY2020 were 306 billion yen with global distribution of products and services in more than 125 countries.
www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005161/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GIGABYTE Powers Telecom AI Transformation with End-to-End Infrastructure at MWC 20262.3.2026 02:00:00 CET | Press release
From AI factories and supercomputing to digital twins, cloud hosting, and edge AI, GIGABYTE enables telecommunications operators to turn network data into intelligence, automation, and new revenue streams. GIGABYTE Technology, a global leader known for its engineering excellence in high-performance computing and AI servers, extends its comprehensive end-to-end AI infrastructure portfolio designed specifically for the telecommunications industry at MWC 2026. GIGABYTE’s end-to-end product solutions enable operators to convert massive volumes of network data into intelligence, automation, and new revenue streams, as telecommunications networks evolve from data carriers into AI-powered digital platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223386188/en/ GIGABYTE Powers Telecom AI Transformation with End-to-End Infrastructure at MWC 2026 From Network Data to AI Value: Building Telco’s AI Factory At the core of the t
Lenovo Unveils Adaptive AI PCs, Modular Concepts, and Lenovo Qira Rollout at MWC 20262.3.2026 00:01:00 CET | Press release
From modular business computing and glasses-free 3D to foldable gaming and system-level AI, Lenovo advances Smarter AI for All At MWC® 2026, Lenovo™ introduces a new generation of adaptive AI devices and forward-looking concepts designed for business professionals, creators, students, and gamers. Headlined by new modular PC architecture, a glasses-free 3D laptop concept, a foldable gaming handheld device, and the initial rollout of Lenovo Qira, Lenovo’s showcase reflects a broader shift in personal computing toward systems that adapt intelligently to people and their environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301217460/en/ Across its portfolio, Lenovo continues to focus on delivering technology that is more personalized, proactive, and protected, while building a unified AI ecosystem that works naturally across devices. “The AI era will not be defined by a single device or application, but by intelligent
TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing1.3.2026 07:00:00 CET | Press release
As MWC Barcelona 2026 highlights the growing role of AI, connectivity, and smarter technology systems, the mobile accessories market is entering a new phase defined by speed and complexity. Product categories continue to expand, designs and styles update faster, and retailers are expected to respond to market changes in shorter cycles. Keeping product lines up to date while managing sourcing efficiently has become a real challenge for retailers and distributors across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121405485/en/ TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing At MWC Barcelona 2026, TVCMALL highlights its role as a leading one-stop mobile accessories wholesaler in Europe, with a clear focus on making wholesale and sourcing easier, faster, and more reliable. With more than 18 years of experience, TVCMALL works closely with 30+ leading retail partners across Europe, supp
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom